Cellect Biotechnology

Immune System Regeneration

Health Tech & Life Sciences
Acquired (Inactive) by Quoin Pharmaceuticals on Nov 2021 - closed due to acquisition

Company Overview

Snapshot

Founded in June 2011 by Nuriel Chirich-Kasbian and Shai Yarkoni, Cellect Biotechnology operates with 11–50 employees. The company raised over $24.26M across 7 funding rounds. In November 2021, Cellect Biotechnology was acquired by Quoin Pharmaceuticals.

Business overview

Cellect Biotechnology is a Health Tech & Life Sciences company focused on developing solutions for immune system regeneration. Its core technology leverages the functional properties of stem cells for identification, selection, and utilization, rather than their appearance. The company's primary product, ApoGraft, is designed to induce apoptosis in mature cells while sparing stem cells, aiming to improve outcomes in bone marrow transplants. Cellect Biotechnology also developed ApoTainer for scalable production of stem cells. The company serves the medical technologies, biotechnology, and pharmaceutical sectors, with applications in regenerative medicine, cancer therapy, and chronic patient care.

Strategic signal

In November 2021, Cellect Biotechnology was acquired by Quoin Pharmaceuticals. This acquisition signifies a strategic consolidation within the biotechnology sector, indicating a potential for accelerated development and commercialization of Cellect's immune system regeneration technologies under a larger corporate umbrella. For investors, this event validates the potential of Cellect's platform and suggests a shift towards integrated solutions in advanced therapeutics.

Company Intelligence Q&A

When was Cellect Biotechnology acquired?
Cellect Biotechnology was acquired by Quoin Pharmaceuticals in November 2021.
What was a key development for Cellect Biotechnology in September 2021?
In September 2021, Cellect Biotechnology announced the bone marrow transplantation of the first patient in the U.S. using its ApoGraft™ technology.
What was the purpose of the registered direct offering in September 2017?
In September 2017, Cellect Biotechnology announced a $4.3 million raise in a registered direct offering.
What was a significant clinical trial milestone for Cellect Biotechnology in October 2020?
In October 2020, Cellect Biotechnology initiated a U.S. clinical trial for its ApoGraft™ product.
What was the outcome of the warrant exercise in May 2020?
In May 2020, Cellect Biotechnology announced the exercise of warrants, resulting in cash proceeds of approximately $1.5 million.

External links